Selvaraj S, Claggett BL, Packer M, et al. - By analyzing 4,744 participants from PARAGON‐HF with available screening lipids, researchers investigated the impacts of sacubitril/valsartan on serum lipids in heart failure with preserved ejection fraction cases. The study sample had an average age of 73±8 years, 52% were females, 43% had diabetes mellitus, and 64% were receiving statin therapy. According to findings, a significant reduction in triglycerides was conferred by sacubitril/valsartan, vs valsartan, an impact that was substantially stronger in those with increased baseline triglycerides. Therapy also brought about modest increases in high‐density lipoprotein cholesterol (HDL‐c) and low‐density lipoprotein cholesterol. The underlying mechanism(s) of alterations in HDL‐c and triglycerides were found to be associated with sacubitril/valsartan’s impacts on natriuretic peptide activity.